Establishing a reliable framework for harnessing the creative power of the scientific crowd

Discovering new medicines is difficult and increasingly expensive. The pharmaceutical industry has responded to this challenge by embracing open innovation to access external ideas. Historically, partnerships were usually bilateral, and the drug discovery process was shrouded in secrecy. This model is rapidly changing. With the advent of the Internet, drug discovery has become more decentralised, bottom-up, and scalable than ever before. The term open innovation is now accepted as just one of many terms that capture different but overlapping levels of openness in the drug discovery process. Many pharmaceutical companies recognise the advantages of revealing some proprietary information in the form of results, chemical tools, or unsolved problems in return for valuable insights and ideas. For example, such selective revealing can take the form of openly shared chemical tools to explore new biological mechanisms or by publicly admitting what is not known in the form of an open call. The essential ingredient for addressing these problems is access to the wider scientific crowd. The business of crowdsourcing, a form of outsourcing in which individuals or organisations solicit contributions from Internet users to obtain ideas or desired services, has grown significantly to fill this need and takes many forms today. Here, we posit that open-innovation approaches are more successful when they establish a reliable framework for converting creative ideas of the scientific crowd into practice with actionable plans.

[1]  G. Rao,et al.  Open Innovation , 2019, Strategic Decisions.

[2]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[3]  Kim Bure,et al.  Open Access Could Transform Drug Discovery: A Case Study of JQ1 , 2016, Expert opinion on drug discovery.

[4]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[5]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[6]  Wen Hwa Lee,et al.  Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery , 2015, PLoS biology.

[7]  Asher Mullard,et al.  2010 FDA drug approvals , 2011, Nature Reviews Drug Discovery.

[8]  N. Savage Competition: Unlikely partnerships , 2016, Nature.

[9]  C. Vakoc,et al.  A rationale to target the SWI/SNF complex for cancer therapy. , 2014, Trends in genetics : TIG.

[10]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[11]  G. Hirsch,et al.  Curing Consortium Fatigue , 2013, Science Translational Medicine.

[12]  B. Huggett Reinventing tech transfer , 2014, Nature Biotechnology.

[13]  S. Knapp,et al.  Probing the epigenome. , 2015, Nature chemical biology.

[14]  Ammon Salter,et al.  Cui Bono? The Selective Revealing of Knowledge and Its Implications for Innovative Activity , 2012 .

[15]  E. Schönbrunn,et al.  An Advanced Tool To Interrogate BRD9. , 2016, Journal of medicinal chemistry.

[16]  A. Edwards,et al.  Reproducibility: Team up with industry , 2016, Nature.

[17]  M. Kinch 2014 in review: FDA approval of new drugs. , 2017, Drug discovery today.

[18]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[19]  Joel Cutcher-Gershenfeld,et al.  Precompetitive consortia in biomedicine—how are we doing? , 2013, Nature Biotechnology.

[20]  A new chapter in innovation , 2016, Nature.

[21]  J. Henkel Selective revealing in open innovation processes: the case of embedded Linux (gekürzte Version) , 2006 .

[22]  Eric Bender,et al.  Challenges: Crowdsourced solutions , 2016, Nature.

[23]  Ragu Bharadwaj,et al.  Crowdsourcing in pharma: a strategic framework. , 2015, Drug discovery today.

[24]  S. Knapp,et al.  Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor , 2016, Journal of medicinal chemistry.

[25]  Arthur S Slutsky,et al.  Preclinical target validation using patient-derived cells , 2015, Nature Reviews Drug Discovery.

[26]  Peter H. Salus,et al.  The Daemon, the Gnu, and the Penguin , 2008 .

[27]  Monika Lessl,et al.  Grants4Targets: an open innovation initiative to foster drug discovery collaborations , 2014, Nature Reviews Drug Discovery.

[28]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[29]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[30]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.